<?xml version="1.0" encoding="utf-8"?>
<search>
  <entry>
    <title>R语言介绍&amp;创建数据集</title>
    <url>/post/ba17bdd8/</url>
    <content><![CDATA[<h5 id="入门级命令"><a href="#入门级命令" class="headerlink" title="入门级命令"></a>入门级命令</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line">search<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#搜索已加载的包,&quot;package:&quot;后面都是已加载的包</span></span><br><span class="line">install.packages<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span> <span class="comment">#手动安装包</span></span><br><span class="line">update.packages<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span> <span class="comment">#手动升级包</span></span><br><span class="line">library<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#调用备用包和捐赠包</span></span><br><span class="line">require<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#调用备用包和捐赠包</span></span><br><span class="line">help.start<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#查看R的帮助网页</span></span><br><span class="line">help<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#查看函数的帮助文档</span></span><br><span class="line">example<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#给出一个函数示例</span></span><br><span class="line"><span class="operator">?</span>mean <span class="comment">#查看mean的帮助文档</span></span><br><span class="line">help.search<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span> <span class="comment">#模糊搜索</span></span><br><span class="line"><span class="operator">?</span><span class="operator">?</span>test <span class="comment">#模糊搜索</span></span><br><span class="line"><span class="comment"># Rstudio安装包可能会报错，用R安装，命令加type=binary</span></span><br></pre></td></tr></table></figure>
<span id="more"></span>
<h5 id="基础运算符-函数"><a href="#基础运算符-函数" class="headerlink" title="基础运算符/函数"></a>基础运算符/函数</h5><p><img src="/post/ba17bdd8/image-20230423003545856-1682234189903-2.png" alt></p>
<p><img src="/post/ba17bdd8/image-20230423004037614-1682234198278-4.png" alt></p>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="built_in">round</span><span class="punctuation">(</span><span class="built_in">pi</span><span class="punctuation">,</span>digits<span class="operator">=</span>x<span class="punctuation">)</span> <span class="comment">#为圆周率取整，&quot;digits=可以省略&quot;</span></span><br></pre></td></tr></table></figure>
<h5 id="数值型对象"><a href="#数值型对象" class="headerlink" title="数值型对象"></a>数值型对象</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line">a<span class="operator">-</span><span class="operator">&lt;</span><span class="number">3</span><span class="operator">+</span><span class="number">5</span> <span class="comment">#估赋值符号的-和&lt;间不能有空格</span></span><br><span class="line">a<span class="operator">=</span><span class="number">8</span> <span class="comment">#不推荐的赋值方法</span></span><br><span class="line">a<span class="operator">+</span><span class="number">3</span><span class="operator">*</span>b<span class="operator">&gt;</span><span class="operator">-</span><span class="built_in">c</span> <span class="comment">#乘号不可省略</span></span><br><span class="line">print<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#显示对象</span></span><br><span class="line"><span class="comment"># R的对象只能以字母开头，可包含字母、数字、下划线、点</span></span><br><span class="line"><span class="comment"># R的对象区分大小写，A和a是不一样的</span></span><br><span class="line"><span class="comment"># 运算顺序：括号→乘方根号→乘除→加减</span></span><br></pre></td></tr></table></figure>
<h5 id="字符型对象"><a href="#字符型对象" class="headerlink" title="字符型对象"></a>字符型对象</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line">A<span class="operator">&lt;=</span><span class="string">&quot;SUN YAT-SEN UNIVERSITY&quot;</span> <span class="comment">#赋值要有引号</span></span><br></pre></td></tr></table></figure>
<h5 id="逻辑型对象"><a href="#逻辑型对象" class="headerlink" title="逻辑型对象"></a>逻辑型对象</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="number">3</span><span class="operator">*</span><span class="number">3</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span> <span class="comment">#结果为TRUE</span></span><br><span class="line"><span class="number">3</span><span class="operator">*</span><span class="number">3</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span> <span class="operator">|</span> <span class="number">3</span><span class="operator">*</span><span class="number">2</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span> <span class="comment">#结果为TRUE</span></span><br><span class="line"><span class="number">3</span><span class="operator">*</span><span class="number">3</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span> <span class="operator">&amp;</span> <span class="number">3</span><span class="operator">*</span><span class="number">2</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span> <span class="comment">#结果为FALSE</span></span><br><span class="line"><span class="punctuation">(</span><span class="number">3</span><span class="operator">*</span><span class="number">3</span><span class="operator">==</span><span class="number">3</span><span class="operator">^</span><span class="number">2</span><span class="punctuation">)</span><span class="operator">+</span><span class="punctuation">(</span><span class="number">5</span><span class="operator">&gt;</span><span class="number">4</span><span class="punctuation">)</span> <span class="comment">#结果为2</span></span><br><span class="line"><span class="comment"># 数值上TRUE=1,FALSE=0</span></span><br></pre></td></tr></table></figure>
<h5 id="工作空间"><a href="#工作空间" class="headerlink" title="工作空间"></a>工作空间</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line">getwd<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#查询工作目录</span></span><br><span class="line">setwd<span class="punctuation">(</span><span class="string">&quot;C:/myprojects/project1&quot;</span><span class="punctuation">)</span> <span class="comment">#查询工作目录</span></span><br><span class="line">dir.create<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#手动创建文件夹</span></span><br><span class="line">save.image<span class="punctuation">(</span><span class="string">&quot;MyFile.Rdata&quot;</span><span class="punctuation">)</span> <span class="comment">#手动保存工作空间</span></span><br><span class="line">ls<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#列出当前工作空间中的所有对象</span></span><br><span class="line">load<span class="punctuation">(</span><span class="punctuation">)</span> <span class="comment">#载入工作空间</span></span><br><span class="line"><span class="comment"># 自动保存的工作空间里，.Rdata是对象，.Rhistory是命令</span></span><br></pre></td></tr></table></figure>
<h5 id="向量"><a href="#向量" class="headerlink" title="向量"></a>向量</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 向量是用于储存数值型、字符型、逻辑型数据的一维数组,可以用函数C()来创建</span></span><br><span class="line">x1<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">2</span><span class="punctuation">,</span><span class="number">4</span><span class="punctuation">,</span><span class="operator">-</span><span class="number">1</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">,</span><span class="number">5</span><span class="punctuation">)</span></span><br><span class="line">x2<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;one&quot;</span><span class="punctuation">,</span><span class="string">&quot;two&quot;</span><span class="punctuation">,</span><span class="string">&quot;three&quot;</span><span class="punctuation">)</span></span><br><span class="line">x3<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="literal">TRUE</span><span class="punctuation">,</span><span class="literal">FALSE</span><span class="punctuation">,</span><span class="literal">TRUE</span><span class="punctuation">,</span><span class="literal">FALSE</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 创建有规律的向量</span></span><br><span class="line">x4<span class="operator">&lt;-</span><span class="number">1</span><span class="operator">:</span><span class="number">5</span></span><br><span class="line">x5<span class="operator">&lt;-</span>seq<span class="punctuation">(</span>from<span class="operator">=</span><span class="number">2</span><span class="punctuation">,</span>to<span class="operator">=</span><span class="number">10</span><span class="punctuation">,</span>by<span class="operator">=</span><span class="number">2</span><span class="punctuation">)</span></span><br><span class="line">x6<span class="operator">&lt;-</span><span class="built_in">rep</span><span class="punctuation">(</span><span class="string">&quot;a&quot;</span><span class="punctuation">,</span>times<span class="operator">=</span><span class="number">4</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 用方括号[]选取向量的子集</span></span><br><span class="line">x<span class="punctuation">[</span><span class="number">5</span><span class="punctuation">]</span></span><br><span class="line">x<span class="punctuation">[</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">4</span><span class="punctuation">,</span><span class="number">6</span><span class="punctuation">,</span><span class="number">7</span><span class="punctuation">)</span><span class="punctuation">]</span></span><br><span class="line"><span class="comment"># 用负号-排除选定的元素</span></span><br><span class="line">x<span class="punctuation">[</span><span class="operator">-</span><span class="punctuation">(</span><span class="number">1</span><span class="operator">:</span><span class="number">3</span><span class="punctuation">)</span><span class="punctuation">]</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># R中的运算都是向量化的</span></span><br><span class="line"><span class="comment"># 若参与运算的两个向量的长度不同，那么短的那个会从第一个元素开始重复利用</span></span><br></pre></td></tr></table></figure>
<p><img src="/post/ba17bdd8/image-20230423111246167-1682234293041-6.png" alt></p>
<p><img src="/post/ba17bdd8/image-20230423111303569-1682234326111-14.png" alt></p>
<h5 id="常用的一些统计函数"><a href="#常用的一些统计函数" class="headerlink" title="常用的一些统计函数"></a>常用的一些统计函数</h5><p><img src="/post/ba17bdd8/image-20230423111501696-1682234337824-16.png" alt></p>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line">a<span class="operator">&lt;-</span><span class="built_in">letters</span><span class="punctuation">[</span><span class="number">1</span><span class="operator">:</span><span class="number">10</span><span class="punctuation">]</span>  <span class="comment">#生成&quot;a&quot;到&quot;j&quot;的10个字母</span></span><br></pre></td></tr></table></figure>
<h5 id="因子"><a href="#因子" class="headerlink" title="因子"></a>因子</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># R中的名义变量和有序变量称为因子</span></span><br><span class="line"><span class="comment"># 用factor()函数定义因子，level水平和label值需要一一对应，这两个都以向量形式表示</span></span><br><span class="line">sex<span class="operator">&lt;-</span><span class="punctuation">(</span><span class="number">1</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">,</span><span class="number">1</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">)</span></span><br><span class="line">sex.f<span class="operator">&lt;-</span>factor<span class="punctuation">(</span>sex<span class="punctuation">,</span>level<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">1</span><span class="operator">:</span><span class="number">2</span><span class="punctuation">)</span><span class="punctuation">,</span>label<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;Male&quot;</span><span class="punctuation">,</span><span class="string">&quot;Female&quot;</span><span class="punctuation">)</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用levelS()函数查看因子属性</span></span><br><span class="line">levelS<span class="punctuation">(</span>sex.f<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># R默认把第一个level当作参考组，可以用relevel()函数修改</span></span><br><span class="line">sex.f1<span class="operator">&lt;-</span>relevel<span class="punctuation">(</span>sex.f<span class="punctuation">,</span>ref<span class="operator">=</span><span class="string">&quot;Female&quot;</span><span class="punctuation">)</span></span><br><span class="line">sex.f1<span class="operator">&lt;-</span>factor<span class="punctuation">(</span>sex<span class="punctuation">,</span>level<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">2</span><span class="operator">:</span><span class="number">1</span><span class="punctuation">)</span><span class="punctuation">,</span>label<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;Female&quot;</span><span class="punctuation">,</span><span class="string">&quot;Male&quot;</span><span class="punctuation">)</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 表示有序变量需要在factor()函数末尾加&quot;ordered=TRUE&quot;选项</span></span><br><span class="line">status<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">1</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">,</span><span class="number">3</span><span class="punctuation">)</span></span><br><span class="line">status.f<span class="operator">=</span>factor<span class="punctuation">(</span>status<span class="punctuation">,</span>level<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">1</span><span class="operator">:</span><span class="number">3</span><span class="punctuation">)</span><span class="punctuation">,</span>label<span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;poor&quot;</span><span class="punctuation">,</span><span class="string">&quot;improved&quot;</span><span class="punctuation">,</span><span class="string">&quot;excellent&quot;</span><span class="punctuation">,</span>ordered<span class="operator">=</span><span class="literal">TRUE</span><span class="punctuation">)</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<h5 id="矩阵"><a href="#矩阵" class="headerlink" title="矩阵"></a>矩阵</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># R中由行和列组成的二维数组称为矩阵，矩阵中每个元素都是同类型的，用matrix()函数定义矩阵</span></span><br><span class="line"><span class="comment"># 矩阵中的元素默认先填充列，若要先填充行，需在末尾增加&quot;byrow=TRUE&quot;</span></span><br><span class="line">mat1<span class="operator">&lt;-</span>matrix<span class="punctuation">(</span><span class="number">1</span><span class="operator">:</span><span class="number">6</span><span class="punctuation">,</span>nrow<span class="operator">=</span><span class="number">2</span><span class="punctuation">)</span></span><br><span class="line">mat2<span class="operator">&lt;-</span>matrix<span class="punctuation">(</span><span class="number">5</span><span class="operator">:</span><span class="number">10</span><span class="punctuation">,</span>nrow<span class="operator">=</span><span class="number">3</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 使用dim()函数获取矩阵的维数，几行几列</span></span><br><span class="line"><span class="built_in">dim</span><span class="punctuation">(</span>mat2<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用%*%做乘法做矩阵的乘法，注意一个的行数需要等于另一个的列数</span></span><br><span class="line">mat1 <span class="operator">%*%</span> mat2</span><br><span class="line"><span class="comment"># 使用t()函数做矩阵的转置</span></span><br><span class="line">t<span class="punctuation">(</span>mat1<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用det()函数求方阵的行列式</span></span><br><span class="line">det<span class="punctuation">(</span>mat3<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用solve()函数求方阵的逆矩阵</span></span><br><span class="line">solve<span class="punctuation">(</span>mat3<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 矩阵的按行按列的运算</span></span><br><span class="line">rowsums<span class="punctuation">(</span>mat1<span class="punctuation">)</span></span><br><span class="line">colsums<span class="punctuation">(</span>mat1<span class="punctuation">)</span></span><br><span class="line">rowmeans<span class="punctuation">(</span>mat1<span class="punctuation">)</span></span><br><span class="line">colmeans<span class="punctuation">(</span>mat1<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用[]选取矩阵的某区域的元素，省略行号或列号表示选取所有行或者所有列</span></span><br><span class="line">mat1<span class="punctuation">[</span><span class="number">1</span><span class="operator">:</span><span class="number">2</span><span class="punctuation">,</span><span class="number">1</span><span class="operator">:</span><span class="number">2</span><span class="punctuation">]</span></span><br></pre></td></tr></table></figure>
<p><img src="/post/ba17bdd8/image-20230423130728622-1682234348539-18.png" alt></p>
<h5 id="数组"><a href="#数组" class="headerlink" title="数组"></a>数组</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 数组可以理解为维数大于2的矩阵</span></span><br><span class="line"><span class="comment"># 用dim()对一维向量加维形成数组</span></span><br><span class="line">A<span class="operator">&lt;-</span><span class="number">1</span><span class="operator">:</span><span class="number">24</span></span><br><span class="line"><span class="built_in">dim</span><span class="punctuation">(</span>A<span class="punctuation">)</span><span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="number">3</span><span class="punctuation">,</span><span class="number">4</span><span class="punctuation">,</span><span class="number">2</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 用array()创建数组，并给各个维度添加名称和标签</span></span><br><span class="line">dim1<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;A1&quot;</span><span class="punctuation">,</span><span class="string">&quot;A2&quot;</span><span class="punctuation">,</span><span class="string">&quot;A3&quot;</span><span class="punctuation">)</span></span><br><span class="line">dim2<span class="operator">&lt;-</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;B1&quot;</span><span class="punctuation">,</span>B2<span class="string">&quot;,&quot;</span>B3<span class="string">&quot;,&quot;</span>B4<span class="string">&quot;)</span></span><br><span class="line"><span class="string">dim3&lt;-c(&quot;</span>C1<span class="string">&quot;,&quot;</span>C2<span class="string">&quot;)</span></span><br><span class="line"><span class="string">array(1:24,dim=c(3,4,2),dimnames=list(dim1,dim2,dim3))</span></span><br></pre></td></tr></table></figure>
<h5 id="列表"><a href="#列表" class="headerlink" title="列表"></a>列表</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 列表可以是任何形式元素的杂糅，用list()函数创建</span></span><br><span class="line">list1<span class="operator">&lt;-</span><span class="built_in">list</span><span class="punctuation">(</span>a<span class="operator">=</span><span class="number">1</span><span class="punctuation">,</span>b<span class="operator">=</span><span class="number">1</span><span class="operator">:</span><span class="number">5</span><span class="punctuation">,</span><span class="built_in">c</span><span class="operator">=</span><span class="built_in">c</span><span class="punctuation">(</span><span class="string">&quot;red&quot;</span><span class="punctuation">,</span><span class="string">&quot;blue&quot;</span><span class="punctuation">,</span><span class="string">&quot;green&quot;</span><span class="punctuation">)</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 很多函数的返回值是一个列表</span></span><br><span class="line">set.seed<span class="punctuation">(</span><span class="number">123</span><span class="punctuation">)</span></span><br><span class="line">dat<span class="operator">&lt;-</span>rnorm<span class="punctuation">(</span><span class="number">10</span><span class="punctuation">)</span></span><br><span class="line">bp<span class="operator">&lt;-</span>boxplot<span class="punctuation">(</span>dat<span class="punctuation">)</span></span><br><span class="line"><span class="built_in">class</span><span class="punctuation">(</span>bp<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 查看列表中某个对象，需要用$符号引用</span></span><br><span class="line">bp<span class="operator">$</span>stats</span><br></pre></td></tr></table></figure>
<h5 id="数据框"><a href="#数据框" class="headerlink" title="数据框"></a>数据框</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 数据框也是一种矩阵，只不过它的列可以是不同类型的元素，使用data.frame()函数创建数据框</span></span><br><span class="line">数据框也可使用<span class="operator">$</span>符号引用特定对象</span><br><span class="line">patients<span class="operator">$</span>age</span><br><span class="line">mean<span class="punctuation">(</span>patients<span class="operator">$</span>age<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<p><img src="/post/ba17bdd8/image-20230423134445808-1682234371012-20.png" alt></p>
<p><img src="/post/ba17bdd8/image-20230423134514155-1682234399377-25.png" alt></p>
<h5 id="数据类型的判断和转换"><a href="#数据类型的判断和转换" class="headerlink" title="数据类型的判断和转换"></a>数据类型的判断和转换</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 以&quot;is.&quot;开头的函数返回值为TRUE或FALSE，以&quot;as.&quot;开头的函数将对象转换为相应的类型</span></span><br></pre></td></tr></table></figure>
<p><img src="/post/ba17bdd8/image-20230423135101747-1682234429014-27.png" alt></p>
<p><img src="/post/ba17bdd8/image-20230423135118570-1682234473379-33.png" alt></p>
<p><img src="/post/ba17bdd8/image-20230423135137721-1682234487781-35.png" alt></p>
<h5 id="调用数据集"><a href="#调用数据集" class="headerlink" title="调用数据集"></a>调用数据集</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 使用data()函数调用datasets包里内置的数据集</span></span><br><span class="line">data<span class="punctuation">(</span>iris<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 调用其他包内的数据集，需要先调用那个包</span></span><br><span class="line">library<span class="punctuation">(</span>MASS<span class="punctuation">)</span></span><br><span class="line">data<span class="punctuation">(</span>bacteria<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<h5 id="R中用于数值模拟的函数"><a href="#R中用于数值模拟的函数" class="headerlink" title="R中用于数值模拟的函数"></a>R中用于数值模拟的函数</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 下列函数用于生成符合特定规则的随机数</span></span><br><span class="line">r1<span class="operator">&lt;-</span>rnorm<span class="punctuation">(</span>n<span class="operator">=</span><span class="number">100</span><span class="punctuation">,</span>mean<span class="operator">=</span><span class="number">0</span><span class="punctuation">,</span>sd<span class="operator">=</span><span class="number">1</span><span class="punctuation">)</span> <span class="comment">#正态分布</span></span><br><span class="line">r2<span class="operator">&lt;-</span>runif<span class="punctuation">(</span>n<span class="operator">=</span><span class="number">10000</span><span class="punctuation">,</span><span class="built_in">min</span><span class="operator">=</span><span class="number">0</span><span class="punctuation">,</span><span class="built_in">max</span><span class="operator">=</span><span class="number">100</span><span class="punctuation">)</span> <span class="comment">#均匀分布</span></span><br><span class="line">r3<span class="operator">&lt;-</span>rbinom<span class="punctuation">(</span>n<span class="operator">=</span><span class="number">80</span><span class="punctuation">,</span>size<span class="operator">=</span><span class="number">100</span><span class="punctuation">,</span>prob<span class="operator">=</span><span class="number">0.1</span><span class="punctuation">)</span> <span class="comment">#二项分布</span></span><br><span class="line">r4<span class="operator">&lt;-</span>rpois<span class="punctuation">(</span>n<span class="operator">=</span><span class="number">50</span><span class="punctuation">,</span>lambda<span class="operator">=</span><span class="number">1</span><span class="punctuation">)</span> <span class="comment">#泊松分布</span></span><br></pre></td></tr></table></figure>
<h5 id="获取其他格式的数据"><a href="#获取其他格式的数据" class="headerlink" title="获取其他格式的数据"></a>获取其他格式的数据</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 读取text文本，header默认是FALSE</span></span><br><span class="line">patients.data<span class="operator">&lt;-</span>read.table<span class="punctuation">(</span><span class="string">&quot;patients.txt&quot;</span><span class="punctuation">,</span>header<span class="operator">=</span><span class="literal">TRUE</span><span class="punctuation">)</span> </span><br><span class="line"><span class="comment"># 读取.csv数据，header默认是TRUE</span></span><br><span class="line">patients.data<span class="operator">&lt;-</span>read.csv<span class="punctuation">(</span><span class="string">&quot;patients.csv&quot;</span><span class="punctuation">)</span> </span><br><span class="line"><span class="comment"># 读取.xlsx文件，使用openxlsx包，readxl包和gdata包</span></span><br><span class="line">library<span class="punctuation">(</span>openxlxs<span class="punctuation">)</span></span><br><span class="line">patients.data<span class="operator">&lt;-</span>read.xlsx<span class="punctuation">(</span><span class="string">&quot;patients.xlsx&quot;</span><span class="punctuation">,</span>sheet<span class="operator">=</span><span class="number">1</span><span class="punctuation">)</span> </span><br><span class="line"><span class="comment"># 读取.sav文件，使用foreign包</span></span><br><span class="line"><span class="comment"># to.data.frame默认是FALSE，如果不设置为TRUE会返回成一个列表</span></span><br><span class="line">library<span class="punctuation">(</span>foreign<span class="punctuation">)</span></span><br><span class="line">patients.data<span class="operator">&lt;-</span>read.spss<span class="punctuation">(</span><span class="string">&quot;patients.sav&quot;</span><span class="punctuation">,</span>to.data.frame<span class="operator">=</span><span class="literal">TRUE</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 读取.xport .dta .epiinfo文件，同样使用foreign包</span></span><br><span class="line">read.xport<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span></span><br><span class="line">read.dta<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span></span><br><span class="line">read.epiinfo<span class="punctuation">(</span><span class="string">&quot;&quot;</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 查看导入的数据集，使用view()函数</span></span><br><span class="line">view<span class="punctuation">(</span>patients.data<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<h5 id="导出数据"><a href="#导出数据" class="headerlink" title="导出数据"></a>导出数据</h5><figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 导出为非.rdata格式文件</span></span><br><span class="line">write.csv<span class="punctuation">(</span>patients.data<span class="punctuation">,</span>file<span class="operator">=</span><span class="string">&quot;patients_data.csv&quot;</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 导出为.rdata文件然后调用</span></span><br><span class="line">save<span class="punctuation">(</span>patients.data<span class="punctuation">,</span>file<span class="operator">=</span><span class="string">&quot;patients.rdata&quot;</span><span class="punctuation">)</span></span><br><span class="line">load<span class="punctuation">(</span><span class="string">&quot;patients.rdata&quot;</span><span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 安装和调用rio包</span></span><br><span class="line">install.packages<span class="punctuation">(</span><span class="string">&quot;rio&quot;</span><span class="punctuation">)</span> <span class="comment">#可使用install_formats()安装依赖包</span></span><br><span class="line">library<span class="punctuation">(</span>rio<span class="punctuation">)</span></span><br><span class="line">data<span class="punctuation">(</span><span class="string">&quot;infert&quot;</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用str()函数查看观测数和变量信息</span></span><br><span class="line">str<span class="punctuation">(</span>infert<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用rio包导入、导出、转换数据，修改变量类型</span></span><br><span class="line">export<span class="punctuation">(</span>infert<span class="punctuation">,</span><span class="string">&quot;infert.csv&quot;</span><span class="punctuation">)</span></span><br><span class="line">convert<span class="punctuation">(</span><span class="string">&quot;infert.csv&quot;</span><span class="punctuation">,</span><span class="string">&quot;infert.sav&quot;</span><span class="punctuation">)</span></span><br><span class="line">infert.data<span class="operator">&lt;-</span>imprt<span class="punctuation">(</span><span class="string">&quot;infert.sav&quot;</span><span class="punctuation">)</span></span><br><span class="line">infert.data<span class="operator">$</span>education<span class="operator">&lt;-</span>as.factor<span class="punctuation">(</span>infert.data<span class="operator">$</span>education<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
<figure class="highlight r"><table><tr><td class="code"><pre><span class="line"><span class="comment"># 安装和调用rio包</span></span><br><span class="line">install.packages<span class="punctuation">(</span><span class="string">&quot;rio&quot;</span><span class="punctuation">)</span> <span class="comment">#可使用install_formats()安装依赖包</span></span><br><span class="line">library<span class="punctuation">(</span>rio<span class="punctuation">)</span></span><br><span class="line">data<span class="punctuation">(</span><span class="string">&quot;infert&quot;</span><span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用str()函数查看观测数和变量信息</span></span><br><span class="line">str<span class="punctuation">(</span>infert<span class="punctuation">)</span></span><br><span class="line"><span class="comment"># 使用rio包导入、导出、转换数据，修改变量类型</span></span><br><span class="line">export<span class="punctuation">(</span>infert<span class="punctuation">,</span><span class="string">&quot;infert.csv&quot;</span><span class="punctuation">)</span></span><br><span class="line">convert<span class="punctuation">(</span><span class="string">&quot;infert.csv&quot;</span><span class="punctuation">,</span><span class="string">&quot;infert.sav&quot;</span><span class="punctuation">)</span></span><br><span class="line">infert.data<span class="operator">&lt;-</span>imprt<span class="punctuation">(</span><span class="string">&quot;infert.sav&quot;</span><span class="punctuation">)</span></span><br><span class="line">infert.data<span class="operator">$</span>education<span class="operator">&lt;-</span>as.factor<span class="punctuation">(</span>infert.data<span class="operator">$</span>education<span class="punctuation">)</span></span><br></pre></td></tr></table></figure>
]]></content>
      <categories>
        <category>R语言</category>
      </categories>
  </entry>
  <entry>
    <title>PCSK9-Protocol</title>
    <url>/post/7559fcbe/</url>
    <content><![CDATA[<div class="hbe hbe-container" id="hexo-blog-encrypt" data-wpm="Oh, this is an invalid password. Check and try again, please." data-whm="OOPS, these decrypted content may changed, but you can still have a look.">
  <script id="hbeData" type="hbeData" data-hmacdigest="dc4ff162834a5d282178f535f95f32c3bc89de1bdeb0f86cda4236986809bda0">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</script>
  <div class="hbe hbe-content">
    <div class="hbe hbe-input hbe-input-default">
      <input class="hbe hbe-input-field hbe-input-field-default" type="password" id="hbePass">
      <label class="hbe hbe-input-label hbe-input-label-default" for="hbePass">
        <span class="hbe hbe-input-label-content hbe-input-label-content-default">这是一项关于PCSK9抑制剂对ACS患者斑块稳定性影响的RCT研究，出于安全考虑，请输入密码以继续浏览</span>
      </label>
    </div>
  </div>
</div>
<script data-pjax src="/lib/hbe.js"></script><link href="/css/hbe.style.css" rel="stylesheet" type="text/css">]]></content>
      <categories>
        <category>研究课题</category>
      </categories>
  </entry>
  <entry>
    <title>Heart Failure with preserved ejection fraction: recent concepts in diagnosis, machanisms and management</title>
    <url>/post/570a6985/</url>
    <content><![CDATA[<h4 id="Abstract"><a href="#Abstract" class="headerlink" title="Abstract"></a>Abstract</h4><ol>
<li><p><strong>One-half</strong> of all patients with heart failure (HF) have heart failure with preserved ejection fraction (HFpEF).</p>
</li>
<li><p>Among patients with HF, <strong>the proportion of hospitalizations and deaths due to cardiac causes decrease as LVEF increases</strong>.</p>
</li>
<li><p>Medication classes that have been efficacious in HFrEF have been less so at higher LVEF ranges.</p>
</li>
<li><p>These observations reflect the burden of <strong>non-cardiac comorbidities as LVEF increases</strong>.</p>
</li>
<li><p>Treatment with <strong>sodium-glucose cotransporter two inhibitors reduce the risk of composite cardiovascular events</strong>, driven by reduced HF hospitalizations; <strong>renin-angiotensin-aldosterone blockers and angiotensin-neprilysin inhibitors result in a minor reduction in HF hospitalizations</strong>.</p>
</li>
<li><p>Classification based on phenotypes<strong> may facilitate a more targeted approach to<br>treatment than LVEF categorization, which </strong>sets arbitrary cut-points when LVEF is a continuum**.</p>
<span id="more"></span>
<p><img src="/post/570a6985/image-20230420141840757.png" alt><img src="/post/570a6985/image-20230420141900244.png" alt></p>
<h4 id="The-evolving-definition-of-HFpEF"><a href="#The-evolving-definition-of-HFpEF" class="headerlink" title="The evolving definition of HFpEF"></a>The evolving definition of HFpEF</h4><p>Recently re-labeled as <strong>‘mildly reduced’ for LVEF 40-50%</strong>. <strong>HFpEF is now defined by normal LVEF ( 50%) along with signs and symptoms of heart failure</strong> after exclusion of prior reduced LVEF and treatable underlying conditions. However, these classifications of HF defined by arbitrary cut-points in LVEF do not appear consistent with recent evidence, which points to a <strong>gradual shift in underlying mechanisms, phenotypes, and response to therapy as LVEF increases, with considerable overlap.</strong></p>
<h4 id="Current-diagnostic-approach-and-its-limitations"><a href="#Current-diagnostic-approach-and-its-limitations" class="headerlink" title="Current diagnostic approach and its limitations"></a>Current diagnostic approach and its limitations</h4><p>HFpEF can be defined theoretically as <strong>the presence of elevated left ventricular (LV) filling<br>pressure at rest or during exercise</strong> <strong>with normal LVEF</strong>. Most guidelines explain HFpEF clinically as (i) <strong>the presence of symptoms and signs</strong> of HF; (ii) an <strong>LVEF ≥ 50%</strong>, (iii) careful <strong>exclusion of “HFpEF mimickers,</strong>” and (iv) evidence of <strong>elevated left ventricular (LV)<br>filling pressure or non-invasive correlates</strong> (elevated E/e ratio, increased left atrial volume,<br>elevated natriuretic peptides [NP]).</p>
<p>Several “HFpEF” randomized clinical trials(RCTs) have <strong>used lower LVEF cut-offs (40-45%)</strong> to maximize event rates and thus attain statistical power.</p>
<p><strong>NP</strong> levels may not always guide diagnosis as they <strong>tend to be lower in HFpEF than HFrEF</strong>, likely due to lower diastolic wall stress and a higher prevalence of obesity.</p>
<p>While these criteria rely on measurements at rest, <strong>left-sided filling pressures increase only with exercise in many patients with HFpEF</strong>; patients who do not experience dyspnea and demonstrate signs of elevated LV filling pressure at rest require advanced testing such as <strong>exercise echocardiography or invasive exercise hemodynamic</strong> to unmask abnormal diastolic reserve.</p>
<p><strong>E/e’</strong> during exercise has been shown to <strong>correlate reasonably well with invasively measured pulmonary capillary wedge pressure (PCWP)</strong>.</p>
<p><strong>Invasive hemodynamics directly measures PCPW during exercise</strong>, although even the diagnostic threshold is still debated (<strong>exercise PCWP≥25 mmHg or ΔPCWP/Δcardiac output slope2.0 mmHg/L/min)</strong>.</p>
<p>Two HFpEF diagnostic algorithms -<strong>the H2FPEF score</strong> and <strong>the European Society of  Cardiology HFA-PEFF algorithm</strong> combine clinical characteristics and diagnostic parameters to distinguish HFpEF from non-cardiac dyspnea.</p>
<p><img src="/post/570a6985/image-20230420141745277.png" alt></p>
<p>Validation of these scores against invasive hemodynamics demonstrated good performance: the <strong>area under the receiver operating characteristic curve was 0.73-0.74</strong>. Still, <strong>up to 23% of patients were misclassified in both scores</strong>, typically in patients with low scores who met invasive HFpEF criteria. Thus, <strong>low scores may not exclude HFpEF</strong>. Furthermore, a substantial proportion of patients have an intermediate probability for HFpEF using this classification system and require further testing.</p>
<p><img src="/post/570a6985/image-20230420141811691.png" alt></p>
<h4 id="HFpEF-mimickers-and-specific-cardiac-aetiologies-of-HFpEF"><a href="#HFpEF-mimickers-and-specific-cardiac-aetiologies-of-HFpEF" class="headerlink" title="HFpEF mimickers and specific cardiac aetiologies of HFpEF"></a>HFpEF mimickers and specific cardiac aetiologies of HFpEF</h4><p>“HFpEF mimickers” such as lung disease, pulmonary embolism, right-sided heart failure secondary to pulmonary hypertension, and renal failure can present similar symptoms and signs. These can be classified into <strong>diseases affecting the myocardium and altering cardiac loading conditions</strong>.</p>
<h4 id="Recent-Insights-in-HFpEF-Pathophysiology"><a href="#Recent-Insights-in-HFpEF-Pathophysiology" class="headerlink" title="Recent Insights in HFpEF Pathophysiology"></a>Recent Insights in HFpEF Pathophysiology</h4><p><strong>In a normal LV, volume increases during diastole are accompanied by minimal pressure increases</strong> due to enhanced diastolic suction; <strong>LV end-diastolic pressure (LVEDP) remains regular with exercise</strong>. </p>
<p>In HFpEF, due to increased chamber stiffness, the diastolic <strong>pressure-volume relationship is shifted upwards and left</strong> compared to a normal LV. Volume changes thus lead to more significant increases in LVEDP. </p>
<p>Additionally, <strong>in most HFpEF patients, the exercise-induced increase in cardiac output is blunted</strong> due to poor contractile reserve and chronotropic incompetence. <strong>In overt HFpEF, the elevated LVEDP persists at rest, resulting in poor exercise tolerance.</strong></p>
<h4 id="Cardiac-and-non-cardiac-mechanisms"><a href="#Cardiac-and-non-cardiac-mechanisms" class="headerlink" title="Cardiac and non-cardiac mechanisms"></a>Cardiac and non-cardiac mechanisms</h4><p><strong>Chronic obstructive pulmonary</strong> disease, <strong>sleep-disordered breathing</strong>, and <strong>lung parenchymal disease</strong> can result in <strong>pulmonary hypertension</strong>, eventually leading to RV failure.</p>
<p><strong>Anemia</strong> is a common comorbidity, contributing to exercise intolerance and increased mortality.</p>
<p><strong>Peripheral vascular dysfunction</strong> is frequent and is postulated to play a role in skeletal muscle dysfunction due to impaired oxygen delivery and extraction.</p>
<p><strong>Chronic kidney disease</strong> is present in 50% of patients, and impaired fluid homeostasis in HFpEF is influenced by renal dysfunction.</p>
<p><strong>Obesity</strong> is both a common comorbidity and a risk factor for developing HFpEF.</p>
<h4 id="HFpEF-phenotypes"><a href="#HFpEF-phenotypes" class="headerlink" title="HFpEF phenotypes"></a>HFpEF phenotypes</h4><p>As LVEF increases, patients with HF are more commonly <strong>women</strong>; more commonly have <strong>hypertension</strong> and <strong>atrial fibrillation</strong>; less commonly have <strong>ischemic heart disease</strong>; and have <strong>lower NP levels</strong>.</p>
<h4 id="Lifestyle-based-therapy"><a href="#Lifestyle-based-therapy" class="headerlink" title="Lifestyle-based therapy"></a>Lifestyle-based therapy</h4></li>
<li><p>In a small RCT in <strong>obese patients with HFpEF</strong>, a calorie restricted <strong>diet</strong> alone or in combination with <strong>exercise training(ET)</strong> was associated with significant <strong>weight loss and an increase in absolute peak oxygen consumption</strong> (VO2peak).</p>
</li>
<li>A <strong>low sodium diet</strong> has been associated with favorable hemodynamic changes in HFpEF.</li>
<li>ET has <strong>beneficial effects in HFpEF and associated comorbidities such as atrial fibrillation and coronary artery disease</strong>. (Both standard moderate continuous training to high intensity interval training). However, <strong>the benefit in VO2peak was not<br>sustained during a 9-month home-based supervised extension of training</strong>.</li>
<li><p><strong>A 6-month exercise</strong> program combining supervised and home-based aerobic exercise resulted in a <strong>significant decrease in the recurrence of atrial fibrillation</strong> and a <strong>reduction in symptom severity at 12 months</strong>.</p>
<h4 id="Medical-therapy"><a href="#Medical-therapy" class="headerlink" title="Medical therapy"></a>Medical therapy</h4></li>
<li><p>To date, <strong>no medical therapy has demonstrated a reduction in CV death in trials of HFpEF</strong>, suggesting the relatively large burden of noncardiac mortality in this group.</p>
</li>
<li>Despite a lack of robust evidence, <strong>diuretics have been the mainstay of HFpEF management</strong> and are recommended for relief of symptoms due to volume overload.</li>
<li><strong>Beta blockers</strong> are often prescribed in HFpEF to treat comorbidities such as <strong>coronary artery disease and atrial fibrillation</strong>. A meta-analysis of three medium-sized RCTs demonstrated <strong>a reduction in all-cause mortality</strong>, <strong>but a vast majority had LVEF &lt;50%</strong>.  Additionally, <strong>beta-blocker type</strong> may <strong>have differential effects across HFpEF phenotypes</strong>.</li>
<li>Renin angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) have an established role in HFrEF, but have been less effective in HFpEF. </li>
<li><strong>Trials of angiotensin-converting enzyme receptor inhibitors (ACEi) and angiotensin II receptor blockers (ARBs)</strong> have <strong>failed to show a significant reduction in all- cause or CV death in HFpEF</strong>, but <strong>have decreased the risk of HF hospitalization</strong>.</li>
<li>The Treatment of Preserved Cardiac Function HF With an Aldosterone Antagonist <strong>(TOPCAT) trial</strong> of the <strong>MRA spironolactone in HFpEF</strong>,<strong>failed to show an overall benefit in the primary composite outcome of CV death or HF hospitalization</strong>. However, in an exploratory analysis including <strong>only patients from the Americas, a small benefit on the primary outcome was noticed</strong>. </li>
<li>In <strong>both TOPCAT and the TOPCAT-Americas subgroup, spironolactone was associated with a reduced risk of HF hospitalization</strong>. </li>
<li>Machine learning analysis of the TOPCAT trial identified <strong>a phenotype characterized by obesity, diabetes, renal disease, and inflammation that exhibited higher CV risk and a better response to spironolactone treatment</strong>.</li>
<li>The angiotensin receptor neprilysin inhibitor <strong>(ARNI) sacubitril-valsartan</strong> did not reduce the composite of CV death or total HF hospitalizations in patients with HF and LVEF ≥45% relative to valsartan in the Prospective Comparison of ARNI With ARB on Global Outcomes in HFpEF <strong>(PARAGON-HF) trial</strong>, but significantly reduced HF hospitalizations.</li>
<li><strong>Patients with elevated troponin</strong> or <strong>recent HF hospitalization</strong> were at higher CV risk and were <strong>more likely to benefit from ARNI</strong>. Also, <strong>benefits were higher in patients previously using MRA</strong>.</li>
<li>These <strong>HFpEF phenotypes</strong> –more likely to be associated with <strong>structural heart disease</strong> and <strong>volume overload</strong>- <strong>may be more responsive to ARNI treatment</strong>.</li>
<li>In the <strong>EMPEROR-Preserved trial</strong>, <strong>sodium-glucose cotransporter 2 inhibitor</strong> (SGLT2i) empagliflozin <strong>reduced the risk of composite CV death or total HF hospitalization in HF with LVEF 40%</strong>. There was <strong>no statistically significant interaction between LVEF and the primary outcome</strong> in the trial, but <strong>benefit did not extend beyond LVEF of 60% in subgroup analysis</strong>.</li>
<li><p>In the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure <strong>(SOLOIST-WHF) trial</strong>, the <strong>dual SGLT2 and SGLT1 inhibitor sotagliflozin reduced the primary outcome of CV death and HF hospitalizations in patients with diabetes and worsening HF (both HFrEF and HFpEF)</strong>, driven by reduced HF hospitalizations.</p>
<h4 id="Sex-and-Racial-differences"><a href="#Sex-and-Racial-differences" class="headerlink" title="Sex and Racial differences"></a>Sex and Racial differences</h4></li>
<li><p>Epidemiological studies and randomized trials demonstrate <strong>a female predominance in HFpEF (50-84%) due to differences in age and risk factors</strong>; adjusting for these differences males and females are at equal risk of developing HFpEF. </p>
</li>
<li><strong>In the TOPCAT-Americas trial</strong>, a post hoc analysis showed <strong>no sex differences in the primary composite outcome</strong>, but <strong>females had a greater reduction in all-cause mortality relative to males with spironolactone </strong>.</li>
<li>In a <strong>prespecified sub-analysis of the PARAGON-HF trial</strong>, <strong>benefits of sacubitril-valsartan on the primary composite outcome</strong> (total HF hospitalizations and CV death) were <strong>sustained up to a higher LVEF in females (up to 60%) than in males (up to 45%)</strong>. </li>
<li>A <strong>meta-analysis of trials of RAAS inhibitors</strong> was consistent with this finding; the <strong>benefits of candesartan, spironolactone and sacubitril-valsartan were sustained to a higher LVEF in females than in males</strong>.</li>
<li><p>There is <strong>no evidence from TOPCAT or EMPEROR-PRESERVED</strong> that <strong>there are racial differences in treatment effect</strong> of MRAs and SGLT2i’s, respectively.</p>
<h4 id="Integration-of-Remote-Monitoring-and-Multidisciplinary-Technology"><a href="#Integration-of-Remote-Monitoring-and-Multidisciplinary-Technology" class="headerlink" title="Integration of Remote Monitoring and Multidisciplinary Technology"></a>Integration of Remote Monitoring and Multidisciplinary Technology</h4><p><strong>Implantable remote pulmonary artery (PA) pressure guided monitoring</strong> for patients with HFpEF, <strong>NYHA Class III symptoms and a prior hospitalization was associated with a 46% reduction</strong> in HF hospitalizations compared to routine care. </p>
<p>The Hemodynamic-Guided Management of HF <strong>(GUIDE-HF) trial</strong>, testing whether this benefit extended to <strong>patients with NYHA class II- IV symptoms and without a prior history hospitalization</strong> found that PA pressure guided management <strong>did not reduce the composite endpoint of all-cause mortality and total HF events</strong>.</p>
<h4 id="Something-interesting"><a href="#Something-interesting" class="headerlink" title="Something interesting"></a>Something interesting</h4></li>
<li><p>Patients with HFmrEF have similar pathophysiology and treatment responses as those with HFrEF.</p>
</li>
<li><p><strong>Cardiac amyloidosis</strong>, for example, is present in up to 13% of HFpEF patients on routine biopsy.</p>
</li>
<li><p>A recently validated risk score can predict patients with HFpEF at risk of sudden cardiac death. </p>
<p><strong>[Adabag S, Langsetmo L. Sudden cardiac death risk prediction in heart failure with<br>preserved ejection fraction. Heart Rhythm 2020;17:358–64. ]</strong></p>
<p><strong>[doi:10.1016/j.hrthm.2019.12.009]</strong></p>
</li>
<li><p>Cardiomyocyte calcium homeostasis was markedly abnormal in diabetic and hypertensive HFpEF but not in ischemic HFpEF.</p>
</li>
<li><p>Obese HFpEF patients have markedly different clinical, hemodynamic and molecular changes compared to non-obese HFpEF patients.</p>
</li>
<li><p>HFpEF caused by microvascular inflammation, HFrEF caused by cardiomyocyte loss.</p>
<h4 id="Conclusion"><a href="#Conclusion" class="headerlink" title="Conclusion"></a>Conclusion</h4><p>LVEF is a continuous variable, and response to HF therapies appears to be graded such that <strong>HF therapies</strong> – including beta-blockers, RAAS inhibitors, ARNI, and SGLT2i - <strong>that reduce both CV death and HF hospitalization at lower LVEFs are less effective at reducing death but continue to reduce HF hospitalization at higher LVEFs beyond 50%</strong>. This points to the <strong>noncardiac mechanisms that underpin or accompany HF as the LVEF increases</strong>, as well as differences in underlying pathophysiology.</p>
<h4 id="Questions"><a href="#Questions" class="headerlink" title="Questions"></a>Questions</h4></li>
<li><p>While the complex interaction of all the proposed non-cardiac mechanisms remain unclear, they appear to <strong>shift from mechanisms in HFrEF at higher ranges of LVEF</strong>, with a gradual change in phenotype and a gradual decrease in the proportion of CV causes of hospitalization and death as LVEF increases.</p>
<h4 id="New-Words"><a href="#New-Words" class="headerlink" title="New Words"></a>New Words</h4><p>algorithm;overt;amenable;supervise;discerning;in light of;entail;concomitant;trait;amenable</p>
</li>
</ol>
]]></content>
      <categories>
        <category>临床文献</category>
      </categories>
  </entry>
  <entry>
    <title>Animal Models of Dysregulated Cardiac Metabolism</title>
    <url>/post/f1ea1d79/</url>
    <content><![CDATA[<h4 id="Abstract"><a href="#Abstract" class="headerlink" title="Abstract"></a>Abstract</h4><p>This review will <strong>summarize metabolic pathways in the heart</strong> and <strong>describe their contribution to maintaining myocardial contractile function</strong> in health and disease. </p>
<h4 id="Overview-of-Cardiac-Metabolism"><a href="#Overview-of-Cardiac-Metabolism" class="headerlink" title="Overview of Cardiac Metabolism"></a>Overview of Cardiac Metabolism</h4><p><img src="/post/f1ea1d79/image-20230425230342841.png" alt></p>
<h4 id="New-words"><a href="#New-words" class="headerlink" title="New words"></a>New words</h4><p>compendium；incessantly；inextricable；deprivation；elucidate；esterified；</p>
]]></content>
      <categories>
        <category>基础文献</category>
      </categories>
  </entry>
  <entry>
    <title>Review: Regulatory RNAs in Heart Failure</title>
    <url>/post/3a2b7726/</url>
    <content><![CDATA[<h4 id="Abstract-Introduce-the-main-idea-of-the-article"><a href="#Abstract-Introduce-the-main-idea-of-the-article" class="headerlink" title="Abstract: Introduce the main idea of the article"></a>Abstract: Introduce the main idea of the article</h4><p><strong>Regulatory RNA</strong>, which we propose abbreviating as reg RNA, can include both protein-coding and noncoding RNAs. We will address the regulation and functional role of messenger RNAs, microRNAs, long noncoding RNAs, and circular RNAs (reg RNAs) in heart failure.</p>
<h4 id="Introduction-Introduce-the-current-status-of-the-diagnosis-and-treatment-of-HF-and-the-urgency-to-focus-on"><a href="#Introduction-Introduce-the-current-status-of-the-diagnosis-and-treatment-of-HF-and-the-urgency-to-focus-on" class="headerlink" title="Introduction: Introduce the current status of the diagnosis and treatment of HF and the urgency to focus on"></a>Introduction: Introduce the current status of the diagnosis and treatment of HF and the urgency to focus on</h4><p> There are <strong>two significant issues</strong>: (1) vast numbers of patients have the condition; and (2) despite treatment advances, the prognosis remains poor. In this article, we introduce the concept of regulatory RNAs (reg RNAs) and gather the current knowledge of the role of RNA molecules with regulatory functions (reg RNAs) in several pathophysiological pathways associated with heart failure, namely cardiac hypertrophy, inflammation, regeneration, and angiogenesis.</p>
 <span id="more"></span>
<h4 id="RNA-FAMILY"><a href="#RNA-FAMILY" class="headerlink" title="RNA FAMILY"></a>RNA FAMILY</h4><p> <img src="/post/3a2b7726/image-20230419122611411.png" alt></p>
<h4 id="Mechanisms-of-action-of-ncRNAs"><a href="#Mechanisms-of-action-of-ncRNAs" class="headerlink" title="Mechanisms of action of ncRNAs"></a>Mechanisms of action of ncRNAs</h4><p> <img src="/post/3a2b7726/image-20230419123738138.png" alt></p>
<h4 id="Short-non-coding-RNA"><a href="#Short-non-coding-RNA" class="headerlink" title="Short non-coding RNA"></a>Short non-coding RNA</h4><p> Composition: <strong>small interfering RNAs</strong>, <strong>piwi-interacting RNAs</strong>, and <strong>miRNAs.</strong></p>
<p> Origin: transcribed as long precursors in which miRNA-containing hairpins are cleaved by the sequential actions of the DROSHA-DGCR8 microprocessor in the nucleus and the DICER-TRBP complex in the cytoplasm.</p>
<p> Size: ~22nt</p>
<p> Function: binds to Argonaute proteins to form the <strong>RNA-induced silencing complex</strong>, which <strong>mediates target-gene silencing by mRNA degradation or translation inhibition</strong>.</p>
<p> Mechanism: MiRNA binding sites have been identified in <strong>3’ and 5’ untranslated regions</strong>, introns, as well as exonic regions of protein-coding mRNAs and lncRNAs.</p>
<p> Others: </p>
<ol>
<li>each miRNA can regulate hundreds of mRNAs, often targeting whole pathways.</li>
<li><p>miRNA families have identical <strong>seed sequences, likely sharing most targets</strong>. The result is a complex network that may be necessary to stabilize central pathways, often displaying high redundancy.</p>
<h4 id="Long-non-coding-RNAs"><a href="#Long-non-coding-RNAs" class="headerlink" title="Long non-coding RNAs"></a>Long non-coding RNAs</h4><p>Characteristics: there are a few examples of lncRNAs displaying a conserved primary sequence, but <strong>conservation is generally weak</strong>. The <strong>secondary structure of lncRNAs is often conserved</strong>, suggesting that structural constraints may be more relevant than the nucleotide sequence in maintaining function. While <strong>many lncRNAs act in trans</strong>, leaving the site of transcription and executing various cellular processes throughout the cell, <strong>others work in cis</strong>, affecting nearby genes’ expression and chromatin state.</p>
<p>Function: </p>
</li>
<li><p>Some cis-acting lncRNAs <strong>regulate the expression of neighboring genes by recruiting regulatory factors to the originating loci</strong>, thereby modulating their function. A prototype of this class of lncRNAs is represented by XIST (X-inactive specific transcript).</p>
</li>
<li>For other lncRNAs such as Airn or Blustr, <strong>the transcription or splicing of the lncRNA and not the transcript itself elicits the regulation of gene expression</strong>.</li>
<li><p>In other lncRNAs, such as lincRNA-p21, the <strong>functional elements are only the DNA sequences within the promoter</strong>, regardless of the encoded RNA or its generation.</p>
<p>Categories:</p>
</li>
<li><p>LncRNAs can <strong>bring together transcriptional repressors and activators</strong>, modulating the rates of RNA Polymerase II initiation and elongation, interacting with various complexes, such as Polycomb Repressive Complex 1 or 2.</p>
</li>
<li>Some nuclear lncRNAs have been implicated in <strong>maintaining nuclear bodies</strong>, such as atomic speckles, built on the architectural lncRNA, NEAT1.</li>
<li>Some <strong>antisense lncRNAs can base-pair with sense-mRNAs</strong>, altering splice-site recognition and spliceosome recruitment.</li>
<li>Other lncRNAs, such as MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), <strong>do not hybridize with the target mRNA but can affect mRNA splicing through cooperation with the splicing machinery</strong>.</li>
<li>Some lncRNAs <strong>act as a molecular scaffold, such as H19</strong>, which favors mRNA degradation mediated by the protein KSRP of myogenin.</li>
<li>Others <strong>bind their complementary sense transcripts and mask miRNA binding sites</strong>, such as BACE1 antisense that protects BACE1 from miR4R85-5p inhibition. </li>
<li>Several lncRNAs <strong>act as competing endogenous RNAs (ceRNAs),</strong> sponging miRNAs, and possibly other regulatory factors. For example, lincMD1 is encoded by the genomic locus containing the miR-206 and miR-133b and works as ceRNA for miR-133 and miR-135.</li>
<li>LncRNAs can also <strong>affect gene expression at the posttranslational level, inducing ubiquitin-mediated proteolysis</strong>. For example, HOTAIR, in addition to its epi-genetic function, can bind to E3 ubiquitin-ligases bearing RNA-binding domains, along with their respective ubiquitination substrates, facilitating their ubiquitination and degradation.</li>
<li>Cir-cRNAs, which are the product of back-splicing events and can accumulate at relatively high levels, act as ceRNA (miRNA sponges). They can also modulate RNA transcription, splicing, turnover, and translation and may have protein-coding potential.</li>
</ol>
<h4 id="Epitranscriptome"><a href="#Epitranscriptome" class="headerlink" title="Epitranscriptome"></a>Epitranscriptome</h4><p><img src="/post/3a2b7726/image-20230419133455699.png" alt></p>
<h4 id="Regulatory-RNAs-in-the-Circulation"><a href="#Regulatory-RNAs-in-the-Circulation" class="headerlink" title="Regulatory RNAs in the Circulation"></a>Regulatory RNAs in the Circulation</h4><p> Increasing evidence shows that cells package and export different molecules, including regRNAs, in extracellular vesicles. These are taken up by recipient cells, where their cargo can induce expressional and functional changes.</p>
<h4 id="Regulatory-RNAs-in-the-Cardiac-Hypertrophy"><a href="#Regulatory-RNAs-in-the-Cardiac-Hypertrophy" class="headerlink" title="Regulatory RNAs in the Cardiac Hypertrophy"></a>Regulatory RNAs in the Cardiac Hypertrophy</h4><p> <img src="/post/3a2b7726/image-20230419172233502.png" alt></p>
<h4 id="Regulatory-RNAs-in-the-Cardiac-Inflammation"><a href="#Regulatory-RNAs-in-the-Cardiac-Inflammation" class="headerlink" title="Regulatory RNAs in the Cardiac Inflammation"></a>Regulatory RNAs in the Cardiac Inflammation</h4><p><img src="/post/3a2b7726/image-20230419165057207.png" alt></p>
<h4 id="Regulatory-RNAs-in-Cardiac-Regeneration"><a href="#Regulatory-RNAs-in-Cardiac-Regeneration" class="headerlink" title="Regulatory RNAs in Cardiac Regeneration"></a>Regulatory RNAs in Cardiac Regeneration</h4><p> <img src="/post/3a2b7726/image-20230419171024964.png" alt></p>
<h4 id="Regulatory-RNAs-in-the-Vascular-System"><a href="#Regulatory-RNAs-in-the-Vascular-System" class="headerlink" title="Regulatory RNAs in the Vascular System"></a>Regulatory RNAs in the Vascular System</h4><p> <img src="/post/3a2b7726/image-20230419174153906.png" alt></p>
<h4 id="Supplement-Something-interesting"><a href="#Supplement-Something-interesting" class="headerlink" title="Supplement: Something interesting"></a>Supplement: Something interesting</h4><ol>
<li>These should be intended as operative categories, <strong>given that the distinction between coding and noncoding RNAs is sometimes blurred, with several cases of RNA species displaying dual roles encoding micro-proteins (less than 100 amino acids)</strong>. Accordingly, <strong>the genomewide analysis of heart translatomes, characterized using ribosome profiling, identified hundreds of microproteins expressed from both lncRNAs and circRNAs.</strong></li>
<li>Noncoding RNAs are <strong>classified for practical reasons according to their size</strong>, less or more than 200 nucleotides long, into short- and long-ncRNAs, respectively.</li>
<li>Regulatory RNAs can be subjected to <strong>methylation</strong>, the most important being <strong>N6-methyladenosine.</strong></li>
<li><strong>miRNAs targeting the five ′- the untranslated region can induce gene expression</strong>.</li>
<li>Though virtually all ncRNAs display at least one putative miRNA binding site, <strong>only a few are expressed at levels sufficiently high to operate as ceRNAs</strong>.</li>
<li>Circulating regRNA profiles have also been reported to <strong>change in response to environmental and lifestyle factors</strong>, such as exercise, diet, and circadian rhythm.</li>
<li>Common mechanisms of successful cardiac regeneration seen in lower vertebrates and neonatal mice <strong>include controlled inflammation and matrix remodeling centering around cardiomyocyte dedifferentiation and proliferation</strong>. In contrast, new cardiomyocyte formation <strong>resulting from endogenous differentiation of progenitor cells after an injury</strong> has been questioned lately.</li>
<li><strong>Coronary vessel remodeling contributes to impaired myocardial contractility</strong>. In contrast, <strong>peripheral vascular remodeling results in decreased compliance</strong>, increased resistance, and reduced capacitance in the arterial circulation, thus increasing the afterload and exacerbating heart failure.</li>
<li><strong>Circular RNAs are expressed and regulated in the vascular system</strong>, although their role in heart failure development is still poorly known.</li>
<li><strong>Endothelial lncRNAs and circRNAs are regulated by hypoxia and may contribute to regulating fibrosis</strong>.</li>
<li>Given their <strong>relative cell-type specific expression and tight temporal and spatial regulation</strong>, regRNAs make attractive therapeutic targets and biomarkers for heart failure.</li>
<li><p>Intriguingly, most of the lncRNA studies described scaffold-based mechanisms (<strong>“sponge effect”</strong>), in which they prevent miRNAs from exerting their roles on mRNAs.</p>
<h4 id="Questions-Something-to-be-solved"><a href="#Questions-Something-to-be-solved" class="headerlink" title="Questions: Something to be solved"></a>Questions: Something to be solved</h4></li>
<li><p>On the other hand, protein-coding sequences display evidence of other embedded functions, <strong>as indicated by constraints on synonymous codon usage.</strong></p>
<h4 id="New-words"><a href="#New-words" class="headerlink" title="New words"></a>New words</h4><p>enormous;nomenclature;attenuate;scavenge;dispensable;pivotal;consecutive;initiatives;indispensable;postulate;consensus;paramount;plausible;subtle;trivial;putative;</p>
<h4 id="References"><a href="#References" class="headerlink" title="References"></a>References</h4></li>
</ol>
]]></content>
      <categories>
        <category>基础文献</category>
      </categories>
  </entry>
  <entry>
    <title>定量资料的统计描述、参数估计和假设检验基础</title>
    <url>/post/1323614/</url>
    <content><![CDATA[<h4 id="频数分布表与分布图"><a href="#频数分布表与分布图" class="headerlink" title="频数分布表与分布图"></a>频数分布表与分布图</h4><h5 id="频数分布表"><a href="#频数分布表" class="headerlink" title="频数分布表"></a>频数分布表</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">频数：n</span><br><span class="line">极差：R=max-min  # 又称全距</span><br><span class="line">组距：i=全距/组段数  # 一般建议分8-15组，取前开后闭区间[a,b)                      </span><br><span class="line">                    # 上限和下限不必是min和max，包含即可</span><br><span class="line">组中值：组段中间的数值</span><br></pre></td></tr></table></figure>
<h5 id="直方图"><a href="#直方图" class="headerlink" title="直方图"></a>直方图</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">当纵轴为频率时，正态概率密度函数曲线下面积为1</span><br></pre></td></tr></table></figure>
<h5 id="分布态势"><a href="#分布态势" class="headerlink" title="分布态势"></a>分布态势</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">对称分布：各组段的频数在左右基本对称</span><br><span class="line">偏态分布：正偏态  # 即右偏态，右边有挖兜</span><br><span class="line">         负偏态  # 即左偏态，左边有挖兜</span><br></pre></td></tr></table></figure>
<h4 id="平均数"><a href="#平均数" class="headerlink" title="平均数"></a>平均数</h4><h5 id="均数"><a href="#均数" class="headerlink" title="均数"></a>均数</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">算数均数：用于描述满足对称分布（正态/近似正态）分布资料的平均水平 </span><br><span class="line">加权均数：当资料中相同观察值较多或是以频数分布表形式呈现时可用加权均数</span><br><span class="line">         在直方图中可表示为Σ频率*组中值</span><br><span class="line">几何均数：用于对数正态分布的资料，或观测值之间存在倍数关系的资料</span><br><span class="line">         计算几何均数前要将观测值对数化</span><br></pre></td></tr></table></figure>
<p>$$ 
G = {\ln ^{ - 1}}\left[ {\left( {\ln {X_1} + ... + \ln {X_n}} \right)/n} \right] = {\ln ^{ - 1}}\left[ {\sum\limits_{i = 1}^n {{X_n}} /n} \right]
$$ </p>
<span id="more"></span>
<h5 id="中位数"><a href="#中位数" class="headerlink" title="中位数"></a>中位数</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">n为奇数：处在(n+1)/2位的观测值</span><br><span class="line">n为偶数：处在n/2和(n+1)/2位的观测值的平均值</span><br></pre></td></tr></table></figure>
<h5 id="百分位数"><a href="#百分位数" class="headerlink" title="百分位数"></a>百分位数</h5><p>$$ 
{P_x} = {L_x} + {{{i_x}} \over {{f_x}}}\left( {nX\%  - \sum {{f_L}} } \right)
$$ </p>
<h4 id="变异指标"><a href="#变异指标" class="headerlink" title="变异指标"></a>变异指标</h4><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">极差：R=max-min</span><br><span class="line">四分位数间距：Q=P~75~-P~25~</span><br></pre></td></tr></table></figure>
<h5 id="方差"><a href="#方差" class="headerlink" title="方差"></a>方差</h5><p>$$ 
{S^2} = {{\sum\limits_{i = 1}^n {{{\left( {{X_i} - \overline X } \right)}^2}} } \over {n - 1}}
$$ </p>
<h5 id="标准差"><a href="#标准差" class="headerlink" title="标准差"></a>标准差</h5><p>$$ 
S = \sqrt {{{\sum\limits_{i = 1}^n {{X_{\rm{i}}}^2 - {{\left( {\sum\limits_{i = 1}^n {{X_i}} } \right)}^2}/n} } \over {n - 1}}}
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">标准差也有“加权标准差”的算法</span><br></pre></td></tr></table></figure>
<h5 id="变异系数"><a href="#变异系数" class="headerlink" title="变异系数"></a>变异系数</h5><p>$$ 
CV = {S \over {\overline X }}{\rm{ \times }}100\%
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">用于比较两个或多个度量衡单位不同的指标的变异程度，如身高和体重</span><br><span class="line">用于比较同一度量衡的变异程度，当它们均数相差较大时，如收缩压和舒张压</span><br><span class="line">变异系数没有单位</span><br></pre></td></tr></table></figure>
<h4 id="正态分布及其应用"><a href="#正态分布及其应用" class="headerlink" title="正态分布及其应用"></a>正态分布及其应用</h4><h5 id="正态分布的概念"><a href="#正态分布的概念" class="headerlink" title="正态分布的概念"></a>正态分布的概念</h5><p>$$ 
f\left( X \right) = {1 \over {\sigma \sqrt {2\pi } }}{e^{ - {{\left( {X - \mu } \right)}^2}/\left( {2{\sigma ^2}} \right)}}
$$ </p>
<p>$$ 
X \sim N\left( {\mu ,{\sigma ^2}} \right)
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">正态分布是单峰分布，以X=μ为中心，左右对称，呈钟形曲线</span><br><span class="line">μ是位置参数，决最高峰的位置；σ是离散参数，越大越矮胖，越小越瘦高</span><br><span class="line">正态曲线下总面积为1，μ±σ区间的面积是68.3%，μ±1.96σ区间的面积是95.0%，μ±2.58σ区间的面积是99.0%</span><br></pre></td></tr></table></figure>
<h5 id="标准正态分布（Z分布）"><a href="#标准正态分布（Z分布）" class="headerlink" title="标准正态分布（Z分布）"></a>标准正态分布（Z分布）</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">可利用Z变化将随机变量标化，将正态分布转换为μ=0，σ^2=1的标准正态分布，即Z~(0，1)</span><br></pre></td></tr></table></figure>
<p>$$ 
Z = \left( {{{X - \mu } \over \sigma }} \right)
$$ </p>
<h5 id="正态分布的判定"><a href="#正态分布的判定" class="headerlink" title="正态分布的判定"></a>正态分布的判定</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">图示法</span><br><span class="line">直方图：横轴是观测值，纵轴是实际频数，可叠加正态概率密度曲线</span><br><span class="line">P-P图：频率-频率图，横轴是实际观测值的累计频率，纵轴是正态分布的理论或期望累计概率</span><br><span class="line">Q-Q图：分位数-分位数图，横轴是实际观测值的分位数，纵轴是正态分布的理论或期望分位数</span><br><span class="line">P-P图和Q-Q图中，散点沿45°对角线分布，则基本服从正态分布，反之符合性不好</span><br></pre></td></tr></table></figure>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">检验法</span><br><span class="line">偏度系数：等于0是对称，大于0是正偏态，小于0是负偏态</span><br><span class="line">总体峰度系数：等于0是正态峰，大于0是尖峭峰，小于0是平阔峰</span><br><span class="line">Kolmogorov-Smirnov：K检验，多用于大样本数据</span><br><span class="line">Shapiro-Wilk：多用于小样本数据</span><br></pre></td></tr></table></figure>
<h5 id="医学参考值的估计"><a href="#医学参考值的估计" class="headerlink" title="医学参考值的估计"></a>医学参考值的估计</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">正态分布法：适合服从或近似服从正态分布的指标</span><br><span class="line">百分位数法：当资料非正态分布时，可用百分位数法估计参考值范围</span><br></pre></td></tr></table></figure>
<p>$$ 
双侧： < \overline X  \pm {Z_{{\alpha  \over 2}}}S
$$ </p>
<p>$$ 
单侧： < \overline X  - {Z_\alpha }S 或 > \overline X  + {Z_\alpha }S
$$ </p>
<h4 id="抽样和抽样误差"><a href="#抽样和抽样误差" class="headerlink" title="抽样和抽样误差"></a>抽样和抽样误差</h4><h5 id="中心极限定理"><a href="#中心极限定理" class="headerlink" title="中心极限定理"></a>中心极限定理</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">从正态分布总体N(μ,σ^2)中随机抽取例数为n的样本，样本均数仍服从正态分布</span><br><span class="line">从非正态分布总体中随机抽样，当样本量足够大(n&gt;50)，样本均数也近似正态分布</span><br><span class="line">样本均数服从的正态分布均数还是μ，标准差转为标准误</span><br></pre></td></tr></table></figure>
<h5 id="标准误"><a href="#标准误" class="headerlink" title="标准误"></a>标准误</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">样本统计量的标准差称为标准误，反映抽样误差的大小</span><br></pre></td></tr></table></figure>
<p>$$ 
{\sigma _{\overline X }} = {\sigma  \over {\sqrt {\rm{n}} }}
$$ </p>
<p>$$ 
{S_{\overline X }} = {S \over {\sqrt {\rm{n}} }}
$$ </p>
<h4 id="Student-t-分布"><a href="#Student-t-分布" class="headerlink" title="Student-t 分布"></a>Student-t 分布</h4><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">适用于正态变量，t变换是Z变换的变体</span><br><span class="line">t分布主要用于总体均数的区间估计和t检验</span><br></pre></td></tr></table></figure>
<p>$$ 
{\rm{t}} = {{\overline X  - \mu } \over {{S_{\overline X }}}} = {{\overline X  - \mu } \over {{S \over {\sqrt n }}}},v = n - 1
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">t分布是单峰分布，以0为中心，左右对称</span><br><span class="line">自由度v越小，t值越分散，曲线矮胖；自由度v越大，t值越集中，曲线瘦高</span><br><span class="line">v趋于无穷大时，t分布的曲线趋近于标准正态分布曲线</span><br><span class="line">|t|越大，P越小</span><br></pre></td></tr></table></figure>
<p><img src="/post/1323614/image-20230424160924458.png" alt></p>
<h5 id="计算总体可信区间"><a href="#计算总体可信区间" class="headerlink" title="计算总体可信区间"></a>计算总体可信区间</h5><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">总体标准差σ未知：按t分布</span><br></pre></td></tr></table></figure>
<p>$$ 
双侧（1-α）可信区间：\overline X  - {t_{{\alpha  \over 2},v}}{S \over {\sqrt n }} < \mu  < \overline X  + {t_{{\alpha  \over 2},v}}{S \over {\sqrt n }}
$$ </p>
<p>$$ 
单侧（1-α）可信区间：\mu  < \overline X  + {t_{\alpha ,v}}{S \over {\sqrt n }}或\mu  > \overline X  - {t_{\alpha ,v}}{S \over {\sqrt n }}
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">总体标准差σ已知 或 σ未知但样本量n足够大（n&gt;50）：按Z分布</span><br></pre></td></tr></table></figure>
<p>$$ 
双侧（1-α）可信区间：\left( {\overline X  \pm {Z_{{\alpha  \over 2},v}}{\sigma  \over {\sqrt n }}} \right)或\left( {\overline X  \pm {Z_{{\alpha  \over 2},v}}{S \over {\sqrt n }}} \right)
$$ </p>
<p>$$
单侧（1-α）可信区间：\mu  > \overline X  - {Z_{{\alpha},v}}{\sigma  \over {\sqrt n }}或\mu  > \overline X  - {Z_{{\alpha},v}}{S \over {\sqrt n }}
$$</p>
<p>$$ 
单侧（1-α）可信区间：\mu  < \overline X  + {Z_{{\alpha},v}}{\sigma  \over {\sqrt n }}或\mu  < \overline X  + {Z_{{\alpha},v}}{S \over {\sqrt n }}
$$ </p>
<figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">可信区间的含义是：从已知总体中以固定n重复随机抽样，根据每个样本可算得一个可信区间，则平均有（1-α）的可信区间包含了总体参数，而不是总体参数落在该范围的可能性是（1-α）</span><br><span class="line">只不过实际上α=0.05是小概率，可以认为在一次随机试验中不太可能发生，所以可以认为“该可信区间包含了总体均数μ”是成立的，其发生错误的概率小于等于0.05</span><br></pre></td></tr></table></figure>
<h4 id="假设检验"><a href="#假设检验" class="headerlink" title="假设检验"></a>假设检验</h4><figure class="highlight plaintext"><table><tr><td class="code"><pre><span class="line">Step 1 → 建立检验假设（零假设H0和备择假设H1），确定检验水准</span><br><span class="line">Step 2 → 计算检验统计量 t t&#x27; Z</span><br><span class="line">Step 3 → 确定P值，作出推断结论</span><br><span class="line">注释1：双尾检验还是双尾检验是根据实际问题决定的，例如比较高原和平原人群的血红蛋白含量可用单尾检验；但一般的，习惯选用双尾检验</span><br><span class="line">注释2：|t|越小，P越大，P≥α，接受原假设，两样本可认为没有差异</span><br><span class="line">注释3：|t|越大，P越小，＜α，拒绝原假设，两样本可认为存在差异</span><br></pre></td></tr></table></figure>
]]></content>
      <categories>
        <category>统计学</category>
      </categories>
  </entry>
  <entry>
    <title>第三期·专题圆桌会</title>
    <url>/post/7a8fb77c/</url>
    <content><![CDATA[<p><strong>2023年4月16日上午，由长学制学生第二党支部举办，其他两个兄弟党支部共同参与的“临床分享圆桌会”在中山大学北校区31层博士生宿舍楼成功举行。支委班子采取了理论学习+专题分享拼盘的创新形式，会上会后收到热烈反响。会议首先由黄渝琴同志首先领学学院党委理论学习中心组下发的3月份学习材料，随后集体观看《一百堂党课·青蒿素和屠呦呦》视频，加深了对同学们对医者身份的认同感，对人民群众日益增长的医疗需要的认识，激发了支部党员同志刻苦求学、认真行医，为“健康中国2030”战略努力奋斗的决心和热情。随后特别嘉宾—来自孙逸仙纪念医院妇科的龙腾飞主治医生，与同学们分享了从湖南到北京再到广州一路成长求学的经历，为同学们的选择二级学科、选择就业环境、科研提升路径、职业生涯发展等方面提出宝贵经验，帮助大家少走弯路，会上陈梓熠、庞晓白等同学分别就关心的就业城市、科研能力提升等问题向龙老师提问，龙医生都耐心地解答给出了自己的看法，鼓励同学们勇于选择、善于选择。最后由中山大学党委组织部专职组织员万海峰老师向龙腾飞医生颁发讲学证书并对会议做点评。万老师肯定了支委班子对活动的筹备工作是完备得当的，肯定了支部响应学校“一融双高”号召的积极性，鼓励支部继续开展系列活动，同时与同学们分享了自己听取龙医生分享后的心得体会，并鼓励青年党员同志能够像龙腾飞老师一样敢闯敢做，阳光开朗。会议由党支部副书记陈俞昆同志主持。</strong></p>
<span id="more"></span>
<p><img src="/post/7a8fb77c/合影.jpg" alt></p>
<center>万海峰老师、龙腾飞老师与同学们合影留念</center>

]]></content>
      <categories>
        <category>学生工作</category>
      </categories>
  </entry>
</search>
